Read by QxMD icon Read

Oral micronised progesterone

Kathryn E Ackerman, Vibha Singhal, Charumathi Baskaran, Meghan Slattery, Karen Joanie Campoverde Reyes, Alexander Toth, Kamryn T Eddy, Mary L Bouxsein, Hang Lee, Anne Klibanski, Madhusmita Misra
OBJECTIVE: Normal-weight oligo-amenorrhoeic athletes (OAA) are at risk for low bone mineral density (BMD). Data are lacking regarding the impact of oestrogen administration on bone outcomes in OAA. Our objective was to determine the effects of transdermal versus oral oestrogen administration on bone in OAA engaged in weight-bearing activity. METHODS: 121 patients with OAA aged 14-25 years were randomised to receive: (1) a 17β-estradiol transdermal patch continuously with cyclic oral micronised progesterone (PATCH), (2) a combined ethinyl estradiol and desogestrel pill (PILL) or (3) no oestrogen/progesterone (NONE)...
October 9, 2018: British Journal of Sports Medicine
John Eden
For a significant minority of women, menopausal symptoms can be very unpleasant; however, many are worried about taking menopausal hormone therapy (MHT) for fear of causing breast cancer. Micronised progesterone (mP4) has been available in Europe since the 1990s and clinical trials have shown that 100 mg oral daily, 200 mg oral sequentially or 100 mg vaginal every second day effectively protect the endometrium from the stimulatory effects of oestrogen. MHT containing mP4 has a significantly lower breast cancer risk than those containing progestins...
February 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
Michelle van der Linden, Karen Buckingham, Cindy Farquhar, Jan A M Kremer, Mostafa Metwally
BACKGROUND: Progesterone prepares the endometrium for pregnancy by stimulating proliferation in response to human chorionic gonadotropin(hCG) produced by the corpus luteum. This occurs in the luteal phase of the menstrual cycle. In assisted reproduction techniques(ART), progesterone and/or hCG levels are low, so the luteal phase is supported with progesterone, hCG or gonadotropin-releasing hormone (GnRH) agonists to improve implantation and pregnancy rates. OBJECTIVES: To determine the relative effectiveness and safety of methods of luteal phase support provided to subfertile women undergoing assisted reproduction...
July 7, 2015: Cochrane Database of Systematic Reviews
Monica Mittal, Michael Savvas, Nitish Narvekar, Nick Panay, Haitham Hamoda
OBJECTIVE: To explore the current clinical attitudes of members of the British Menopause Society to the management of premature ovarian insufficiency. DESIGN: An electronic cross-sectional questionnaire survey. SETTING: Members of the British Menopause Society. POPULATION: All members of the British Menopause Society with a valid email address. METHOD: Completion of an electronic survey. MAIN OUTCOME MEASURES: Investigations and treatment options and preferences for the management of women with premature ovarian insufficiency...
September 2014: Post Reproductive Health
Nick Panay
The adverse outcomes seen in the Women's Health Initiative (WHI) (1) were mainly due to an over-dosage of hormones in a relatively elderly population. However, fundamental differences exist between conjugated equine estrogens and 17 beta estradiol and between medroxyprogesterone acetate and natural progesterone. It is likely that these differences also contributed to the adverse outcomes in WHI, which were contrary to the cardiovascular benefits seen in previous observational trials. Recent studies of cardiovascular risk markers in younger women have been designed using predominantly estradiol and natural progesterone (transdermal and oral) as the primary interventions...
June 2014: Post Reproductive Health
Savas Karakus, Gurkan Kiran, Harun Ciralik
BACKGROUND: The vaginal route is more effective than the other drug delivery routes for some specific indications. AIM: To compare the efficacy of a vaginal progesterone preparation with that of oral dydrogesterone. METHODS: A total of 69 women with irregular dysfunctional uterine bleeding were randomly assigned into one of two groups: oral dydrogesterone group (n = 35) and vaginal progesterone group (n = 34). At the end of a three-month treatment period, the women were re-evaluated...
December 2009: Australian & New Zealand Journal of Obstetrics & Gynaecology
Faustino R Pérez-López, José L Cuadros-López, Ana M Fernández-Alonso, Angela M Cuadros-Celorrio, Rosa M Sabatel-López, Peter Chedraui
OBJECTIVE: To assess fatal cardiovascular disease (FCD) risk among women in early post-menopausal years, as evaluated with the Systematic Coronary Risk Evaluation (SCORE) scale. DESIGN: This was a retrospective study of parallel cohorts. Two hundred seventy-three healthy post-menopausal women. Participants received one of the following hormone treatment (HT) regimens: transdermal estradiol (50 microg) (n = 99), sequential cyclic HT with transdermal estradiol (50 microg/day) plus 200 mg/day natural micronised oral progesterone (cycle days 12-25) (n = 63) and combined HT using transdermal estradiol (50 microg) plus 100 mg/day of micronised oral progesterone (n = 61)...
July 2010: Gynecological Endocrinology
Angiolo Gadducci, Nicoletta Biglia, Stefania Cosio, Piero Sismondi, Andrea Riccardo Genazzani
The relevance of the progestagen component in combined hormone replacement therapy (HRT) for breast cancer risk has been long debated. In vitro studies have shown that progestins exert both genomic transcriptional and non-genomic effects that can enhance the proliferation, invasiveness and spread of breast cancer cells. According to a novel hypothesis, progestins can still activate cancer stem cells in patients with pre-existing, clinically undetected breast cancer. However, some experimental and clinical data suggest that different progestins may have a different impact on the pathophysiology of malignant breast cells...
December 2009: Gynecological Endocrinology
S Bozhinova, P Bozhinov
Epilepsy is a disease, closely connected with sex-hormones and can lead to adverse repercussion on the reproductive health. The ovarial hormones influence excitation of neurocells membranes and have a lot of effects on brain, leading to provoking epileptic activity. The progesteron decrease and the estrogens increase the brain excitation, that's why estrogens (act like a proconvulsant) are proconvulsant and progesteron is anticonvulsant. The aim of this study is to evaluate therapeutic abilities of Utrogestan (micronising progesteron) for treatment of abortions and climacteric amplifications in women with epilepsy...
2005: Akusherstvo i Ginekologii︠a︡
L Andréen, O Spigset, A Andersson, S Nyberg, T Bäckström
OBJECTIVES: To investigate the pharmacokinetics of progesterone, allopregnanolone and pregnanolone after treatment with a low oral dose of progesterone. METHODS: Eight postmenopausal women were given a single oral dose of 20 mg of micronised progesterone on Day 1 and 20 mg twice daily on Days 2-7. Blood samples for the analysis of progesterone, allopregnanolone and pregnanolone were collected, and pharmacokinetic parameters were calculated. RESULTS: After ingestion of a single dose, areas under the plasma concentration-time curve (AUC) from 0 to 12 h for progesterone, allopregnanolone and pregnanolone were 127%, 196% and 119% higher than the corresponding AUCs estimated to be caused by endogenous production...
June 20, 2006: Maturitas
Baidya Nath Chakravarty, Hasibul Hasan Shirazee, Purvita Dam, Sourendra Kanta Goswami, Ratna Chatterjee, Sanghamitra Ghosh
The objective of this prospective, randomised study was to compare the efficacy, safety and tolerability of vaginal micronised progesterone with oral dydrogesterone as luteal phase support after in-vitro fertilisation (IVF). A total of 430 women underwent IVF/intracytoplasmic sperm injection (ICSI) treatment. Long protocol gonadotropin releasing hormone analogue down-regulation was followed by gonadotropin stimulation. Human chorionic gonadotropin was given when two or more follicles reached > or = 17 mm...
December 2005: Journal of Steroid Biochemistry and Molecular Biology
Karine Lacut, Emmanuel Oger, Grégoire Le Gal, Marie-Thérèse Blouch, Jean-François Abgrall, Véronique Kerlan, Pierre-Yves Scarabin, Dominique Mottier et al.
C-reactive protein (CRP) is one of the main independent predictors of cardiovascular events. Oral post-menopausal estrogen replacement therapy (ERT) increases CRP levels, but the effect of transdermal ERT is not well documented. CRP, interleukine-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were evaluated in a randomised study of 196 healthy postmenopausal women, who were allocated to receive continuous oral estradiol-1beta, (n=63) or transdermal estradiol-1beta, (n=68) both combined with micronised progesterone, or place-bo (n=65)...
July 2003: Thrombosis and Haemostasis
A Thijs, W M van Baal, M J van der Mooren, P Kenemans, A M Dräger, P C Huijgens, C D A Stehouwer
BACKGROUND: Hormone replacement therapy (HRT) increases the risk of cardiovascular morbidity in postmenopausal women under certain circumstances. Part of this effect may be the result of the influence of HRT on blood platelets. We studied the effect of short-term oral hormone replacement therapy (unopposed oestradiol or sequentially combined oestradiol and trimegestone or dydrogesterone) on platelet activation parameters in healthy postmenopausal women. DESIGN: We designed a prospective, randomised, placebo-controlled 12-week study...
August 2002: European Journal of Clinical Investigation
N Mendoza, J A Pisón, M Fernández, M C Sánchez, J Malde, J A Miranda
OBJECTIVE: To compare compliance, symptom control, bleeding patterns, lipid and biochemical changes in postmenopausal women treated with three regimens of HRT. METHODS: In a prospective, randomised, group comparative study, with 165 patients, the effects on the aforementioned parameters, as well as treatment compliance and side effects were studied with oral tibolone 2.5 mg per day, with cyclic combined regimen of transdermal oestrogen and progestogen (transdermal patch of 17beta-oestradiol 50 microg/day during 14 days and transdermal patch of 17beta-oestradiol 50 microg/day plus 0...
April 25, 2002: Maturitas
M Wahab, F Al-Azzawi
UNLABELLED: Trimegestone is a novel norpregnane progestin, which has a potent progesterone receptor and very low androgen receptor affinities but no detectable affinity to oestrogen receptor. Trimegestone has been developed for use in conjunction with oestrogen for postmenopausal hormone replacement therapy (HRT). The dose of trimegestone required for endometrial safety was optimised in a dose ranging study. Oral trimegestone was administered at 0.05, 0.1, 0.25 and 0.5 mg/day, days 15 - 28 along with continuous oral micronised oestradiol at 2 mg daily...
September 2001: Expert Opinion on Investigational Drugs
A Lemay, S Dodin, L Turcot, F Déchêne, J C Forest
OBJECTIVES: The objectives of this study were to assess serum lipid changes in response to an oral estrogen combined with progesterone (Group A) as compared with pravastatin (Group B) and to evaluate the additive effects of the sequential addition of statin to hormonal replacement therapy (HRT) and of HRT to statin. METHODS: Thirty-seven of 63 hypercholesterolemic menopausal women initially submitted to a 4-month diet were randomised to oral conjugated estrogens (0...
December 14, 2001: Maturitas
K Wyatt, P Dimmock, P Jones, M Obhrai, S O'Brien
OBJECTIVE: To evaluate the efficacy of progesterone and progestogens in the management of premenstrual syndrome. DESIGN: Systematic review of published randomised, placebo controlled trials. STUDIES REVIEWED: 10 trials of progesterone therapy (531 women) and four trials of progestogen therapy (378 women). MAIN OUTCOME MEASURES: Proportion of women whose symptoms showed improvement with progesterone preparations (suppositories and oral micronised)...
October 6, 2001: BMJ: British Medical Journal
S E Fineberg
Despite evidence that supports the beneficial effects of postmenopausal hormone replacement therapy (HRT), concerns remain about its possible adverse effects. However, entry into the postmenopausal state is associated with many characteristics of the insulin resistance syndrome, including increased cardiovascular morbidity and mortality, accretion of generalised and visceral adiposity and insulin resistance. Studies carried out in postmenopausal women have revealed that an increase in visceral obesity is associated with an increase in androgenicity that, in turn, is associated with type 2 (non-insulin-dependent) diabetes mellitus...
December 2000: Drugs & Aging
P O'Leary, P Feddema, K Chan, M Taranto, M Smith, S Evans
OBJECTIVE: The use of topically applied micronised ('natural') progesterone as a substitute for synthetic oestrogens and progestogen preparations is controversial. The aim of this study was to examine the changes in blood and salivary concentrations of progesterone following a single topical application of a progesterone cream. PATIENTS AND MEASUREMENTS: We investigated six premenopausal women in the luteal phase and six postmenopausal women to determine the short-term changes in serum, urinary and salivary progesterone concentrations following a single 64 mg topical application of micronised progesterone...
November 2000: Clinical Endocrinology
M Wahab, J Thompson, F Al-Azzawi
OBJECTIVE: To assess the value of identifying endometrial structural abnormalities at baseline hysteroscopy in predicting the pattern of bleeding in postmenopausal women treated with hormone replacement therapy. DESIGN: A randomised, double-blind, dose-ranging study. SETTING: A teaching hospital in the UK. POPULATION: One hundred and seventy-six healthy postmenopausal women. METHODS: Women were randomised to receive one of four doses of oral trimegestone (0...
March 2000: BJOG: An International Journal of Obstetrics and Gynaecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"